1
硕腾公司
硕腾公司是全球领先的纯动物保健企业，在兽药和宠物医疗领域占据主导地位。公司成立于1952年，最初为辉瑞的动物保健部门，后于2013年完成里程碑式的首次公开募股（IPO），总部位于美国新泽西州帕西帕尼。2025年，硕腾年营收达950亿美元，在11个国家运营着23个生产基地
2
默沙东公司（动物保健部门）
默克动物保健（北美以外地区称MSD动物保健）是制药巨头默克公司旗下的动物保健业务部门，依托母公司650.1亿美元总营收及每年超过70亿美元的研发引擎。总部位于美国新泽西州拉威市。该部门2025年动物保健业务收入为640亿美元，在50多个国家设有生产基地，由7.5万名母公司员工提供支持。
品牌
默克动物保健
成立时间
1940
员工规模
7.5万（母公司默克）
覆盖范围
产品覆盖150+个国家，直接办事处覆盖50+个国家
生产基地
全球生产覆盖50+个国家；堪萨斯州德索托扩建项目8.95亿美元；奥地利克雷姆斯设施1.85亿美元
总部
美国
市场
纽交所：parent
3
勃林格殷格翰国际有限公司
勃林格殷格翰是全球最大的家族私有制药企业，其动物保健业务位列全球兽药行业前三强。这家家族企业创立于1885年，总部位于德国莱茵河畔英格尔海姆，2025年实现总净销售额2775.1亿欧元，其中动物保健业务贡献487.5亿欧元。公司在13个国家设有20个生产基地，全球员工总数达…
4
礼蓝动物保健公司
Elanco Animal Health是一家全球顶尖的动物保健公司，自2018年从礼来公司分拆以来，经历了深刻的战略转型。公司总部位于美国印第安纳州格林菲尔德，2025年营收达471.5亿美元（同比增长6%，有机增长7%），在17个生产基地拥有9300名员工。Elanco…
5
爱德士实验室公司
IDEXX Laboratories 是兽医诊断领域无可争议的全球领导者，其商业模式与传统动物制药企业存在根本性差异。公司成立于1983年，总部位于美国缅因州韦斯特布鲁克，2025年实现营收430.4亿美元（同比增长10.42%），拥有11,000名员工。IDEXX构建了无与伦比的"剃刀与刀片"生态系统：通…
品牌
爱德士
成立时间
1983
员工规模
1.1万
覆盖范围
产品覆盖175+个国家
生产基地
制造基地在缅因州（韦斯特布鲁克、斯卡伯勒）和佐治亚州（罗斯威尔）；全球80多个参考实验室
总部
美国
市场
纳斯达克：IDXX
6
诗华动物保健公司
Ceva Santé Animale 是全球增长最快的独立动物保健公司之一，以其员工与私募股权联合体所有权结构及卓越的生产布局而著称。公司成立于1999年，总部位于法国利布尔讷，2024年营收约17.7亿欧元（约合19亿美元），在全球拥有7,000名员工、32个生产基地及21个研发中心。<…
7
威霸公司
Virbac 是一家专注于动物健康的制药公司，由一位兽医于1968年创立，秉持"由兽医创立，为兽医服务"的经营理念。公司总部位于法国普罗旺斯-阿尔卑斯-蓝色海岸大区卡罗斯，2025年营收达14.65亿欧元（约合16亿美元）（有机增长7.9%），在12个国家设有12个生产基地，拥有6400名员工
8
Dechra Topco有限公司
Dechra Pharmaceuticals（现为Dechra Topco Limited）是一家高度专业化的制造商，专注于小众伴侣动物治疗市场——内分泌学、皮肤病学、眼科学和重症监护麻醉。公司成立于1997年，总部位于英国柴郡诺斯维奇，于2024年由EQT以具有里程碑意义的44.36亿英镑收购完成私有化。2024财年，公司实现约7.96亿…
9
中牧实业股份有限公司
中牧实业股份有限公司（CAHIC）是中国动物保健领域的国有骨干企业，也是国内最大的国有控股兽药平台。公司成立于1998年，总部位于中国北京，2025年实现营业收入62.05亿元人民币（约合8.6亿美元），在多个GMP生产基地拥有约5000名员工。2025年经营活动现金流净额达11.58亿元人民币，同比增长1…
10
天津瑞普生物技术股份有限公司
瑞普生物（天津瑞普生物技术股份有限公司）是中国领先的上市动物保健制造商，也是该全球前十强排名中唯一总部位于亚洲的企业。公司成立于1998年，总部位于中国天津，2025年实现营收33.98亿元人民币（约合4.7亿美元）（同比增长7.72%），其中宠物健康板块猛增24.39%至8.58亿元人民币。瑞普生物的核心…
常见问题
我们的排名是如何生成的？
VerityRank采用严谨、数据驱动的方法对全球领先的兽药和宠物保健公司进行排名。我们的评估框架权衡四个同等重要的维度，每个维度占最终得分的25%。市场影响力衡量全球收入规模、伴侣动物细分市场份额以及通过兽医从业者调查和搜索引擎可见性数据评估的品牌认知度。
品牌声誉维度评估产品质量一致性、发表在同行评审兽医期刊上的临床疗效数据以及监管合规记录。创新与研发考察各公司研发投入占收入的比例、开发的新型活性药物成分或生物平台数量、近期FDA和EMA批准情况，以及在单克隆抗体和mRNA疫苗等高增长治疗领域的专利组合实力。
可持续性与道德考量包括制造环境足迹、动物福利标准、供应链透明度以及抗菌药物管理计划。所有数据均来自公司年报（2025财年）、SEC文件、同行评审兽医文献和独立市场研究数据库。排名每年更新，以反映最新的财务和运营数据。
品牌声誉维度评估产品质量一致性、发表在同行评审兽医期刊上的临床疗效数据以及监管合规记录。创新与研发考察各公司研发投入占收入的比例、开发的新型活性药物成分或生物平台数量、近期FDA和EMA批准情况，以及在单克隆抗体和mRNA疫苗等高增长治疗领域的专利组合实力。
可持续性与道德考量包括制造环境足迹、动物福利标准、供应链透明度以及抗菌药物管理计划。所有数据均来自公司年报（2025财年）、SEC文件、同行评审兽医文献和独立市场研究数据库。排名每年更新，以反映最新的财务和运营数据。
How Do We Generate Our Rankings?
VerityRank employs a rigorous, data-driven methodology to rank the world's leading veterinary pharmaceutical and pet healthcare companies. Our evaluation framework weighs four equally important dimensions, each contributing 25% to the final score. Market Influence measures global revenue scale, companion animal segment market share, and brand recognition assessed through veterinary practitioner surveys and search engine visibility data.
The Brand Reputation dimension evaluates product quality consistency, clinical efficacy data published in peer-reviewed veterinary journals, and regulatory compliance records. Innovation & R&D examines each company's R&D investment as a percentage of revenue, the number of novel active pharmaceutical ingredients or biologic platforms developed, recent FDA and EMA approvals, and patent portfolio strength in high-growth therapeutic areas such as monoclonal antibodies and mRNA-based vaccines.
Sustainability & Ethics accounts for manufacturing environmental footprint, animal welfare standards, supply chain transparency, and antimicrobial stewardship programs. All data is sourced from company annual reports (FY2025), SEC filings, peer-reviewed veterinary literature, and independent market research databases. Rankings are updated annually to reflect the latest financial and operational data.
The Brand Reputation dimension evaluates product quality consistency, clinical efficacy data published in peer-reviewed veterinary journals, and regulatory compliance records. Innovation & R&D examines each company's R&D investment as a percentage of revenue, the number of novel active pharmaceutical ingredients or biologic platforms developed, recent FDA and EMA approvals, and patent portfolio strength in high-growth therapeutic areas such as monoclonal antibodies and mRNA-based vaccines.
Sustainability & Ethics accounts for manufacturing environmental footprint, animal welfare standards, supply chain transparency, and antimicrobial stewardship programs. All data is sourced from company annual reports (FY2025), SEC filings, peer-reviewed veterinary literature, and independent market research databases. Rankings are updated annually to reflect the latest financial and operational data.
兽药和宠物保健的关键领域是什么？
兽药和宠物医疗行业涵盖了多种产品类别，已远远超出传统化学药物。核心细分市场包括宠物疫苗（类别9.1）——从核心狂犬病疫苗和多价联合疫苗到针对伴侣动物癌症的尖端mRNA平台疫苗——以及宠物杀虫剂（类别9.2），以异噁唑啉类口服制剂如Simparica Trio和NexGard为主，可提供长达数月的跳蚤、蜱虫和体内寄生虫保护。
宠物治疗药物（类别9.3）是增长最快、价值最高的细分市场，由针对犬骨关节炎的单克隆抗体疗法（Librela、Solensia）和针对特应性皮炎的JAK抑制剂（Zenrelia）驱动。宠物诊断检测（类别9.4）由IDEXX Laboratories开创，通过即时检测分析仪和参考实验室网络已成为重要的临床类别。其他高增长细分市场包括宠物营养补充剂（类别9.5）用于关节和肠道健康、宠物日常护理产品（类别9.6）涵盖牙科和皮肤科应用，以及专业老年宠物药物（类别9.7）针对衰老伴侣动物的慢性肾病、甲状腺功能亢进和认知功能障碍。
该行业正经历从传统小分子仿制药向大分子生物制品和精准诊断的决定性转变，仅生物制品细分市场预计到2035年将以两位数的速度增长。
宠物治疗药物（类别9.3）是增长最快、价值最高的细分市场，由针对犬骨关节炎的单克隆抗体疗法（Librela、Solensia）和针对特应性皮炎的JAK抑制剂（Zenrelia）驱动。宠物诊断检测（类别9.4）由IDEXX Laboratories开创，通过即时检测分析仪和参考实验室网络已成为重要的临床类别。其他高增长细分市场包括宠物营养补充剂（类别9.5）用于关节和肠道健康、宠物日常护理产品（类别9.6）涵盖牙科和皮肤科应用，以及专业老年宠物药物（类别9.7）针对衰老伴侣动物的慢性肾病、甲状腺功能亢进和认知功能障碍。
该行业正经历从传统小分子仿制药向大分子生物制品和精准诊断的决定性转变，仅生物制品细分市场预计到2035年将以两位数的速度增长。
What Are the Key Segments Within Veterinary Pharmaceuticals & Pet Healthcare?
The veterinary pharmaceuticals and pet healthcare industry encompasses a diverse range of product categories that have evolved far beyond traditional chemical drugs. The core segments include pet vaccines (Category 9.1)—ranging from core rabies and multivalent combination vaccines to cutting-edge mRNA platform vaccines targeting companion animal cancers—and pet parasiticides (Category 9.2), dominated by isoxazoline-class oral formulations like Simparica Trio and NexGard that provide months-long protection against fleas, ticks, and internal parasites.
Pet therapeutic medications (Category 9.3) represent the highest-growth and highest-value segment, driven by monoclonal antibody therapies targeting canine osteoarthritis (Librela, Solensia) and JAK inhibitors for atopic dermatitis (Zenrelia). Pet diagnostic testing (Category 9.4), pioneered by IDEXX Laboratories, has become an essential clinical category through point-of-care analyzers and reference laboratory networks. Additional high-growth segments include pet nutritional supplements (Category 9.5) for joint and gut health, pet daily care products (Category 9.6) spanning dental and dermatological applications, and specialty geriatric pet medications (Category 9.7) addressing chronic kidney disease, hyperthyroidism, and cognitive dysfunction in aging companion animals.
The industry is witnessing a decisive shift from traditional small-molecule generics toward large-molecule biologics and precision diagnostics, with the biologics segment alone projected to grow at double-digit rates through 2035.
Pet therapeutic medications (Category 9.3) represent the highest-growth and highest-value segment, driven by monoclonal antibody therapies targeting canine osteoarthritis (Librela, Solensia) and JAK inhibitors for atopic dermatitis (Zenrelia). Pet diagnostic testing (Category 9.4), pioneered by IDEXX Laboratories, has become an essential clinical category through point-of-care analyzers and reference laboratory networks. Additional high-growth segments include pet nutritional supplements (Category 9.5) for joint and gut health, pet daily care products (Category 9.6) spanning dental and dermatological applications, and specialty geriatric pet medications (Category 9.7) addressing chronic kidney disease, hyperthyroidism, and cognitive dysfunction in aging companion animals.
The industry is witnessing a decisive shift from traditional small-molecule generics toward large-molecule biologics and precision diagnostics, with the biologics segment alone projected to grow at double-digit rates through 2035.
宠物人性化趋势如何推动该行业的增长？
“宠物人性化”大趋势——将伴侣动物视为家庭成员，并给予其等同于人类的医疗保健——是兽药行业最强大的需求驱动力。在发达市场，超过70%的宠物主人现在将宠物视为家庭成员，这直接转化为对以前仅用于人类的先进医疗治疗的支付意愿。这种行为转变创造了一个4025亿美元的全球市场，并以3.56%的复合年增长率持续增长，其中高端治疗领域（单克隆抗体、专业诊断、慢性病管理）的增长率显著更高。
宠物人性化趋势最明显地体现在专业治疗类别的爆炸性增长中。犬骨关节炎——曾经用普通非甾体抗炎药治疗——现在使用靶向NGF的单克隆抗体（硕腾的Librela），每次注射花费数百美元。犬特应性皮炎——以前用类固醇治疗——现在使用JAK抑制剂（Zenrelia）和IL-31单克隆抗体（Befrena）治疗。猫慢性肾病——老年猫的主要死亡原因——通过磷酸盐结合剂（Ipakitine）和ACE抑制剂管理，需要持续的处方依从性。
这一趋势也推动了对先进诊断的需求，兽医诊所越来越多地采用与人类医院实验室相当的内置化学分析仪、血液学系统和AI驱动的形态学平台。爱德士2025年安装了超过1900台inVue Dx分析仪——每台都能产生持续的试剂收入——这体现了宠物人性化如何在整个兽医医疗价值链中转化为持久、高利润的商业模式。
宠物人性化趋势最明显地体现在专业治疗类别的爆炸性增长中。犬骨关节炎——曾经用普通非甾体抗炎药治疗——现在使用靶向NGF的单克隆抗体（硕腾的Librela），每次注射花费数百美元。犬特应性皮炎——以前用类固醇治疗——现在使用JAK抑制剂（Zenrelia）和IL-31单克隆抗体（Befrena）治疗。猫慢性肾病——老年猫的主要死亡原因——通过磷酸盐结合剂（Ipakitine）和ACE抑制剂管理，需要持续的处方依从性。
这一趋势也推动了对先进诊断的需求，兽医诊所越来越多地采用与人类医院实验室相当的内置化学分析仪、血液学系统和AI驱动的形态学平台。爱德士2025年安装了超过1900台inVue Dx分析仪——每台都能产生持续的试剂收入——这体现了宠物人性化如何在整个兽医医疗价值链中转化为持久、高利润的商业模式。
How Is the Pet Humanization Trend Driving Growth in This Industry?
The "Pet Humanization" megatrend—the treatment of companion animals as family members deserving human-equivalent healthcare—is the single most powerful demand driver in the veterinary pharmaceutical industry. Across developed markets, over 70% of pet owners now consider their pets as family members, directly translating into willingness to spend on advanced medical treatments previously reserved for humans. This behavioral shift has created a $402.5 billion global market that continues to grow at 3.56% CAGR, with the premium therapeutic segment (monoclonal antibodies, specialty diagnostics, chronic disease management) growing at significantly higher rates.
The pet humanization trend manifests most visibly in the explosive growth of specialty therapeutic categories. Canine osteoarthritis—once managed with generic NSAIDs—is now treated with NGF-targeting monoclonal antibodies (Zoetis's Librela) costing hundreds of dollars per injection. Canine atopic dermatitis, previously managed with steroids, is now treated with JAK inhibitors (Zenrelia) and IL-31 monoclonal antibodies (Befrena). Feline chronic kidney disease, a leading cause of mortality in aging cats, is managed with phosphate binders (Ipakitine) and ACE inhibitors requiring ongoing prescription compliance.
This trend is also driving demand for advanced diagnostics, with veterinary practices increasingly adopting in-clinic chemistry analyzers, hematology systems, and AI-driven morphology platforms comparable to human hospital laboratories. IDEXX's 2025 installation of over 1,900 inVue Dx analyzers—each generating recurring reagent revenue—exemplifies how pet humanization translates into durable, high-margin business models across the veterinary healthcare value chain.
The pet humanization trend manifests most visibly in the explosive growth of specialty therapeutic categories. Canine osteoarthritis—once managed with generic NSAIDs—is now treated with NGF-targeting monoclonal antibodies (Zoetis's Librela) costing hundreds of dollars per injection. Canine atopic dermatitis, previously managed with steroids, is now treated with JAK inhibitors (Zenrelia) and IL-31 monoclonal antibodies (Befrena). Feline chronic kidney disease, a leading cause of mortality in aging cats, is managed with phosphate binders (Ipakitine) and ACE inhibitors requiring ongoing prescription compliance.
This trend is also driving demand for advanced diagnostics, with veterinary practices increasingly adopting in-clinic chemistry analyzers, hematology systems, and AI-driven morphology platforms comparable to human hospital laboratories. IDEXX's 2025 installation of over 1,900 inVue Dx analyzers—each generating recurring reagent revenue—exemplifies how pet humanization translates into durable, high-margin business models across the veterinary healthcare value chain.
中国公司在全球兽药市场中扮演什么角色？
以中牧股份和瑞普生物为代表的中国动物保健公司正在成为全球兽药领域的重要力量，尽管其当前影响力主要仍局限于国内。中牧股份作为国有企业，2025年收入达62.05亿元人民币（约合8.6亿美元），经营现金流高达11.58亿元人民币（同比增长175.89%），为其从传统牲畜疫苗向高端伴侣动物治疗药物的战略转型提供了巨额财务资源。瑞普生物是中国最大的上市动物保健制造商，拥有11个超大型生产基地、94条自动化生产线和500多个产品批准——这是亚洲最大的单一国家制造足迹。
中国竞争优势的核心在于西方竞争对手难以复制的独特“API到终端”垂直整合模式。瑞普的生态系统通过中瑞供应链将其庞大的制造设施直接连接到瑞派宠物医院网络的14,000多个兽医终端，消除了多层分销商利润。这种从工厂到患者的闭环使得定价显著低于西方竞争对手，同时通过上游API合成控制保持健康利润。
然而，中国公司在全球市场渗透方面面临重大障碍：有限的国际监管批准（FDA、EMA）、在北美和欧洲的品牌认知度极低，以及产品管线仍集中于疫苗和仿制药而非新型生物制品。瑞普的宠物健康板块2025年实现8.58亿元人民币（同比增长24.39%），显示出强劲的国内势头，但中国兽药企业的国际化将需要多年的监管投入、临床试验数据生成和品牌建设，才能在其本土市场真正挑战西方现有企业。
中国竞争优势的核心在于西方竞争对手难以复制的独特“API到终端”垂直整合模式。瑞普的生态系统通过中瑞供应链将其庞大的制造设施直接连接到瑞派宠物医院网络的14,000多个兽医终端，消除了多层分销商利润。这种从工厂到患者的闭环使得定价显著低于西方竞争对手，同时通过上游API合成控制保持健康利润。
然而，中国公司在全球市场渗透方面面临重大障碍：有限的国际监管批准（FDA、EMA）、在北美和欧洲的品牌认知度极低，以及产品管线仍集中于疫苗和仿制药而非新型生物制品。瑞普的宠物健康板块2025年实现8.58亿元人民币（同比增长24.39%），显示出强劲的国内势头，但中国兽药企业的国际化将需要多年的监管投入、临床试验数据生成和品牌建设，才能在其本土市场真正挑战西方现有企业。
What Role Do Chinese Companies Play in the Global Veterinary Pharma Market?
Chinese animal health companies, led by CAHIC (China Animal Husbandry Industry Co.) and Ringpu Biology, are emerging as significant forces in the global veterinary pharmaceutical landscape, though their current influence remains primarily domestic. CAHIC, a state-owned enterprise, generated CNY 6.205 billion (~USD 860 million) in 2025 revenue with extraordinary CNY 1.158 billion in operating cash flow (up 175.89% YoY), providing massive financial resources for its strategic pivot from traditional livestock vaccines into premium companion animal therapeutics. Ringpu Biology, China's largest publicly-traded animal health manufacturer, operates 11 mega-scale production bases with 94 automated lines and 500+ product approvals—the largest single-country manufacturing footprint in Asia.
The Chinese competitive advantage centers on a unique "API-to-endpoint" vertical integration model that Western competitors cannot easily replicate. Ringpu's ecosystem connects its massive manufacturing facilities through the Zhongrui Supply Chain directly to the Ringpai Pet Hospital network's 14,000+ veterinary endpoints, eliminating multiple layers of distributor margins. This factory-to-patient closed loop enables pricing that significantly undercuts Western competitors while maintaining healthy margins through upstream API synthesis control.
However, Chinese companies face substantial barriers to global market penetration: limited international regulatory approvals (FDA, EMA), minimal brand recognition in North America and Europe, and a pipeline still concentrated on vaccines and generics rather than novel biologics. The pet health segment at Ringpu achieved CNY 858 million in 2025 (up 24.39% YoY), demonstrating strong domestic momentum, but the internationalization of Chinese veterinary pharma will require years of regulatory investment, clinical trial data generation, and brand-building before they can genuinely challenge the Western incumbents in their home markets.
The Chinese competitive advantage centers on a unique "API-to-endpoint" vertical integration model that Western competitors cannot easily replicate. Ringpu's ecosystem connects its massive manufacturing facilities through the Zhongrui Supply Chain directly to the Ringpai Pet Hospital network's 14,000+ veterinary endpoints, eliminating multiple layers of distributor margins. This factory-to-patient closed loop enables pricing that significantly undercuts Western competitors while maintaining healthy margins through upstream API synthesis control.
However, Chinese companies face substantial barriers to global market penetration: limited international regulatory approvals (FDA, EMA), minimal brand recognition in North America and Europe, and a pipeline still concentrated on vaccines and generics rather than novel biologics. The pet health segment at Ringpu achieved CNY 858 million in 2025 (up 24.39% YoY), demonstrating strong domestic momentum, but the internationalization of Chinese veterinary pharma will require years of regulatory investment, clinical trial data generation, and brand-building before they can genuinely challenge the Western incumbents in their home markets.
兽医诊所应如何评估药品供应商？
评估制药和诊断供应商的兽医诊所应优先考虑价格以外的四个关键因素：制造可靠性、临床证据质量、生态系统整合和供应链韧性。制造可靠性——公司持续生产和交付产品而不中断的能力——至关重要。行业领先制造商已投资数十亿美元建设自有、冗余的生产设施，以降低单点故障风险。硕腾在11个国家拥有23个生产基地，默克动物保健在堪萨斯州投资8.95亿美元，这些都体现了这一承诺。诊所应询问供应商的制造应急计划，特别是对于冷链生物制品，温度偏差可能危及整批产品。
临床证据质量将优质供应商与仿制药制造商区分开来。本报告中排名靠前的公司——硕腾、默克、勃林格殷格翰——维持着稳健的临床试验项目，并在同行评审的兽医期刊上发表文章，为兽医提供具有统计显著性的疗效和安全性数据。对于诊断供应商，爱德士的专有参考实验室网络每年处理数百万份样本，生成庞大的临床数据库，不断优化其参考区间和诊断算法。
生态系统整合已成为供应商选择中的决定性因素，尤其是在诊断领域。爱德士的VetConnect PLUS软件将仪器结果、参考实验室数据和患者历史整合到一个统一的临床工作流程中，创造了显著的转换成本。提供互补产品组合的制药供应商——例如礼蓝动保整合的皮肤病学套件，涵盖JAK抑制剂、IL-31单克隆抗体和局部疗法——使诊所能够标准化治疗方案并简化库存管理。最后，供应链韧性应通过每个供应商的制造地理多样性、冷链物流能力以及在近期全球中断事件中的表现来评估。
临床证据质量将优质供应商与仿制药制造商区分开来。本报告中排名靠前的公司——硕腾、默克、勃林格殷格翰——维持着稳健的临床试验项目，并在同行评审的兽医期刊上发表文章，为兽医提供具有统计显著性的疗效和安全性数据。对于诊断供应商，爱德士的专有参考实验室网络每年处理数百万份样本，生成庞大的临床数据库，不断优化其参考区间和诊断算法。
生态系统整合已成为供应商选择中的决定性因素，尤其是在诊断领域。爱德士的VetConnect PLUS软件将仪器结果、参考实验室数据和患者历史整合到一个统一的临床工作流程中，创造了显著的转换成本。提供互补产品组合的制药供应商——例如礼蓝动保整合的皮肤病学套件，涵盖JAK抑制剂、IL-31单克隆抗体和局部疗法——使诊所能够标准化治疗方案并简化库存管理。最后，供应链韧性应通过每个供应商的制造地理多样性、冷链物流能力以及在近期全球中断事件中的表现来评估。
How Should Veterinary Practices Evaluate Pharmaceutical Suppliers?
Veterinary practices evaluating pharmaceutical and diagnostic suppliers should prioritize four critical factors beyond price: manufacturing reliability, clinical evidence quality, ecosystem integration, and supply chain resilience. Manufacturing reliability—a company's ability to consistently produce and deliver products without interruption—is paramount. The industry's leading manufacturers have invested billions in owned, redundant production facilities to mitigate single-point-of-failure risks. Zoetis's 23 manufacturing sites across 11 countries and Merck Animal Health's $895M Kansas expansion exemplify this commitment. Practices should inquire about suppliers' manufacturing contingencies, particularly for cold-chain biologics where temperature excursions can compromise entire batches.
Clinical evidence quality differentiates premium suppliers from commodity generics manufacturers. The top-ranked companies in this report—Zoetis, Merck, Boehringer Ingelheim—maintain robust clinical trial programs publishing in peer-reviewed veterinary journals, providing veterinarians with statistically significant efficacy and safety data. For diagnostic suppliers, IDEXX's proprietary reference laboratory network processes millions of samples annually, generating an immense clinical data repository that continuously refines its reference intervals and diagnostic algorithms.
Ecosystem integration has become a decisive factor in supplier selection, particularly in diagnostics. IDEXX's VetConnect PLUS software integrates instrument results, reference lab data, and patient history into a unified clinical workflow, creating meaningful switching costs. Pharmaceutical suppliers offering complementary product portfolios—such as Elanco's integrated dermatology suite spanning JAK inhibitors, IL-31 mAbs, and topical therapies—enable practices to standardize treatment protocols and simplify inventory management. Finally, supply chain resilience should be assessed through each supplier's manufacturing geographic diversification, cold-chain logistics capabilities, and track record during recent global disruptions.
Clinical evidence quality differentiates premium suppliers from commodity generics manufacturers. The top-ranked companies in this report—Zoetis, Merck, Boehringer Ingelheim—maintain robust clinical trial programs publishing in peer-reviewed veterinary journals, providing veterinarians with statistically significant efficacy and safety data. For diagnostic suppliers, IDEXX's proprietary reference laboratory network processes millions of samples annually, generating an immense clinical data repository that continuously refines its reference intervals and diagnostic algorithms.
Ecosystem integration has become a decisive factor in supplier selection, particularly in diagnostics. IDEXX's VetConnect PLUS software integrates instrument results, reference lab data, and patient history into a unified clinical workflow, creating meaningful switching costs. Pharmaceutical suppliers offering complementary product portfolios—such as Elanco's integrated dermatology suite spanning JAK inhibitors, IL-31 mAbs, and topical therapies—enable practices to standardize treatment protocols and simplify inventory management. Finally, supply chain resilience should be assessed through each supplier's manufacturing geographic diversification, cold-chain logistics capabilities, and track record during recent global disruptions.